Cell line · CVCL_0236
Papers53
1 to 20 of 53
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CGM23 corresponds to a pan-coronavirus lipopeptide inhibitor potently inhibiting virion fusion. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LAT1/SLC7A5-mediated amino acid uptake is regulated by redox signals triggered by formyl-peptide receptor 2. | FEBS J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1. | Exp Dermatol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and characterization of a novel telomerase alternative splicing isoform that protects lung cancer cells from chemotherapy induced cell death. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. | Elife | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Dynamics of TERT regulation via alternative splicing in stem cells and cancer cells. | PLoS One | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Ectopically Expressed Meiosis-Specific Cancer Testis Antigen HORMAD1 Promotes Genomic Instability in Squamous Cell Carcinomas. | Cells | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Intronic Cis-Element DR8 in hTERT Is Bound by Splicing Factor SF3B4 and Regulates hTERT Splicing in Non-Small Cell Lung Cancer. | Mol Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. | Mol Cancer Ther | 2022 | Its Methods give the RRID and name the line | PubMed | |
| ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. | Cell Rep Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0236/papers